TrmD as an Antibacterial Target: A Review of Small-Molecule Inhibitor Discovery Strategies
- TrmD, a SPOUT-family bacterial tRNA methyltransferase without a human counterpart, is highlighted as a validated antibacterial target amid rising antimicrobial resistance.
- The review catalogs strategies used to discover small-molecule TrmD inhibitors—fragment-based design, high-throughput and virtual screening, click-chemistry-enabled direct-to-biology methods, molecular hybridization, and prodrug approaches.
- It synthesizes structural features and structure-activity relationships across these diverse chemical scaffolds to inform future inhibitor optimization.
💡 Points
TrmD's lack of a human ortholog is the real selling point here — a wide therapeutic window without the usual off-target liability, which is rare enough in antibacterial discovery to justify the review's existence. The click-chemistry/direct-to-biology entries jump out as the underexploited lane: fast SAR turnaround without carrying every analog through full synthesis, exactly what a fragmented, scaffold-diverse target like this needs before someone finally nails spectrum and PK.
TrmD: A Promising Antibacterial Target and Its Small-Molecule Inhibitors ↗